Literature DB >> 26667610

Nasopharyngeal carriage of Streptococcus pneumoniae and other bacteria in the 7th year after implementation of the pneumococcal conjugate vaccine in the Netherlands.

Astrid A T M Bosch1, Marlies A van Houten2, Jacob P Bruin3, Alienke J Wijmenga-Monsuur4, Krzysztof Trzciński5, Debby Bogaert5, Nynke Y Rots4, Elisabeth A M Sanders6.   

Abstract

After introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in the infant national immunization program (NIP) in the Netherlands in 2006, Streptococcus pneumoniae strains of the non-vaccine serotype 19A emerged and became the dominant serotype in carriage in children and their parents. Similar patterns were observed in other European countries and the United States. Increases in carriage rates of Staphylococcus aureus and non-typeable (NT) Haemophilus influenzae were also observed. After switching of PCV7 to 10-valent vaccine (PCV10) in 2011, a new carriage surveillance study was performed in the winter of 2012/2013. Nasopharyngeal carriage of S. pneumoniae, H. influenzae, S. aureus, and Moraxella catarrhalis was determined by conventional culture in 330 PCV10-vaccinated 11-month-old children, 330 PCV7-vaccinated 24-month-old children, and their parents. Carriage prevalence was compared with similar carriage studies conducted in 2005, 2009, and 2010/2011. Although serotype 19A remained the most frequently carried pneumococcal serotype in children, prevalence of 19A significantly declined in PCV7-vaccinated 24-month-old children (14% to 8%, p=0.01), but less in PCV10-vaccinated 11-month-old children (12% to 9%, p=0.31). Carriage of H. influenzae remained stable at an elevated level (65% in 11-month-olds and 69% in 24-month-olds), while the carriage of S. aureus returned to pre-PCV7 levels in 11-month-old children (14% in 2010/2011 to 7% in 2012/2013), but not in 24-month-olds (remained at 7%). Our results might indicate a new balance between replacing non-vaccine pneumococcal serotypes and other potential pathogenic bacteria in nasopharyngeal carriage. Carriage studies are valuable tools in assessing vaccine effects on pathogens circulating in the population, for evaluation of PCV impact, and in predicting changes in respiratory and invasive disease.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Haemophilus influenzae; Moraxella catarrhalis; NL40288.094.12; NTR3614; Nasopharyngeal carriage; Pneumococcal conjugate vaccination (PCV); Staphylococcus aureus; Streptococcus pneumoniae

Mesh:

Substances:

Year:  2015        PMID: 26667610     DOI: 10.1016/j.vaccine.2015.11.060

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  29 in total

1.  The complexity of serotype replacement of pneumococci.

Authors:  Orsolya Dobay
Journal:  Hum Vaccin Immunother       Date:  2019-06-13       Impact factor: 3.452

Review 2.  Potential impact of a Moraxella catarrhalis vaccine in COPD.

Authors:  Antonia C Perez; Timothy F Murphy
Journal:  Vaccine       Date:  2017-02-06       Impact factor: 3.641

3.  Other age groups than children need to be considered as carriers of Streptococcal pneumoniae serotypes.

Authors:  Hans-Christian Slotved
Journal:  Hum Vaccin Immunother       Date:  2016-06-20       Impact factor: 3.452

4.  Why we need a vaccine for non-typeable Haemophilus influenzae.

Authors:  Marina Cerquetti; Maria Giufrè
Journal:  Hum Vaccin Immunother       Date:  2016-05-12       Impact factor: 3.452

5.  Postnatal exposure to household disinfectants, infant gut microbiota and subsequent risk of overweight in children.

Authors:  Mon H Tun; Hein M Tun; Justin J Mahoney; Theodore B Konya; David S Guttman; Allan B Becker; Piush J Mandhane; Stuart E Turvey; Padmaja Subbarao; Malcolm R Sears; Jeffrey R Brook; Wendy Lou; Tim K Takaro; James A Scott; Anita L Kozyrskyj
Journal:  CMAJ       Date:  2018-09-17       Impact factor: 8.262

6.  The Relevance of a Novel Quantitative Assay to Detect up to 40 Major Streptococcus pneumoniae Serotypes Directly in Clinical Nasopharyngeal and Blood Specimens.

Authors:  Melina Messaoudi; Milen Milenkov; Werner C Albrich; Mark P G van der Linden; Thomas Bénet; Monidarin Chou; Mariam Sylla; Patricia Barreto Costa; Nathalie Richard; Keith P Klugman; Hubert P Endtz; Gláucia Paranhos-Baccalà; Jean-Noël Telles
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

7.  Molecular surveillance on Streptococcus pneumoniae carriage in non-elderly adults; little evidence for pneumococcal circulation independent from the reservoir in children.

Authors:  Anne L Wyllie; Lidewij W Rümke; Kayleigh Arp; Astrid A T M Bosch; Jacob P Bruin; Nynke Y Rots; Alienke J Wijmenga-Monsuur; Elisabeth A M Sanders; Krzysztof Trzciński
Journal:  Sci Rep       Date:  2016-10-07       Impact factor: 4.379

8.  Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.

Authors:  Alienke J Wijmenga-Monsuur; Els van Westen; Mirjam J Knol; Riet M C Jongerius; Marta Zancolli; David Goldblatt; Pieter G M van Gageldonk; Irina Tcherniaeva; Guy A M Berbers; Nynke Y Rots
Journal:  PLoS One       Date:  2015-12-10       Impact factor: 3.240

9.  Molecular surveillance of nasopharyngeal carriage of Streptococcus pneumoniae in children vaccinated with conjugated polysaccharide pneumococcal vaccines.

Authors:  Anne L Wyllie; Alienke J Wijmenga-Monsuur; Marlies A van Houten; Astrid A T M Bosch; James A Groot; Jody van Engelsdorp Gastelaars; Jacob P Bruin; Debby Bogaert; Nynke Y Rots; Elisabeth A M Sanders; Krzysztof Trzciński
Journal:  Sci Rep       Date:  2016-04-05       Impact factor: 4.379

10.  Development of Upper Respiratory Tract Microbiota in Infancy is Affected by Mode of Delivery.

Authors:  Astrid A T M Bosch; Evgeni Levin; Marlies A van Houten; Raiza Hasrat; Gino Kalkman; Giske Biesbroek; Wouter A A de Steenhuijsen Piters; Pieter-Kees C M de Groot; Paula Pernet; Bart J F Keijser; Elisabeth A M Sanders; Debby Bogaert
Journal:  EBioMedicine       Date:  2016-05-26       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.